N-trans-p-coumaroyl-L-tyrosine: from Theobroma cacao; structure in first source [MeSH]
trans-Dideoxyclovamide : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 15825666 |
| CHEMBL ID | 4129983 |
| CHEBI ID | 181160 |
| MeSH ID | M0461304 |
| Synonym |
|---|
| CHEBI:181160 |
| (2s)-3-(4-hydroxyphenyl)-2-[[(e)-3-(4-hydroxyphenyl)prop-2-enoyl]amino]propanoic acid |
| trans-dideoxyclovamide |
| l-tyrosine, n-[(2e)-3-(4-hydroxyphenyl)-1-oxo-2-propenyl]- |
| 77201-66-2 |
| n-trans-p-coumaroyltyrosine |
| ncgc00385093-01_c18h17no5_l-tyrosine, n-[(2e)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]- |
| NCGC00385093-01 |
| FS-8366 |
| bdbm50272457 |
| chembl4129983 , |
| (2s)-3-(4-hydroxyphenyl)-2-(3-(4-hydroxyphenyl)prop-2-enoylamino)propanoic acid |
| n-trans-p-coumaroyl-l-tyrosine |
| l-tyrosine, n-(3-(4-hydroxyphenyl)-1-oxo-2-propenyl)-, (e)- |
| NBS8NYY2M5 , |
| n-p-coumaroyltyrosine |
| l-tyrosine, n-((2e)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl)- |
| n-(e)-p-coumaroyl-l-tyrosine |
| n-coumaroyltyrosine |
| n-((2e)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl)-l-tyrosine |
| unii-nbs8nyy2m5 |
| AKOS040763557 |
| Class | Description |
|---|---|
| tyrosine derivative | An amino acid derivative resulting from reaction of tyrosine at the amino group or the carboxy group, any substitution of phenyl hydrogens, or from the replacement of any hydrogen of tyrosine by a heteroatom. The definition normally excludes peptides containing tyrosine residues. |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 100.0000 | AID1495590 |
| Nitric oxide synthase, inducible | Homo sapiens (human) | IC50 | 2.1000 | AID1395931 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1395931 | Inhibition of LPS-induced iNOS in human BV2 cells after 4 hrs by DAF-FMDA dye-based fluorescence assay | 2018 | European journal of medicinal chemistry, May-10, Volume: 151ISSN: 1768-3254 | Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo. |
| AID1495591 | Inhibition of amyloid beta (1 to 42) (unknown origin) fibril formation at 100 uM after 24 hrs by silicotungstic acid staining based transmission electron microscopic analysis | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 ISSN: 1464-3391 | Structure-activity relationship of clovamide and its related compounds for the inhibition of amyloid β aggregation. |
| AID1495590 | Inhibition of amyloid beta (1 to 42) (unknown origin) aggregation after 24 hrs by thioflavin T fluorescence assay | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 ISSN: 1464-3391 | Structure-activity relationship of clovamide and its related compounds for the inhibition of amyloid β aggregation. |
| AID1395928 | Anti-neuroinflammatory activity in human BV2 cells assessed as reduction in LPS-induced NO production at 10 uM preincubated for 4 hrs followed by LPS stimulation for 24 hrs by Griess assay relative to control | 2018 | European journal of medicinal chemistry, May-10, Volume: 151ISSN: 1768-3254 | Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo. |
| AID1395930 | Cytotoxicity against human BV2 cells assessed as reduction in cell viability after 24 hrs by MTT assay | 2018 | European journal of medicinal chemistry, May-10, Volume: 151ISSN: 1768-3254 | Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo. |
| AID1395929 | Anti-neuroinflammatory activity in human BV2 cells assessed as reduction in LPS-induced NO production preincubated for 4 hrs followed by LPS stimulation for 24 hrs by Griess assay | 2018 | European journal of medicinal chemistry, May-10, Volume: 151ISSN: 1768-3254 | Synthesis and biological evaluation of clovamide analogues as potent anti-neuroinflammatory agents in vitro and in vivo. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| clovamide | tyrosine derivative | 2018 | 2018 | 6.0 | high | 0 | 0 | 0 | 0 | 1 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tyrosine | amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical | 2003 | 2003 | 21.0 | high | 0 | 0 | 0 | 1 | 0 | 0 | |
| clovamide | tyrosine derivative | 2003 | 2003 | 21.0 | high | 0 | 0 | 0 | 1 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute Confusional Senile Dementia | 0 | 2018 | 2018 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Alzheimer Disease | 0 | 2018 | 2018 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Atherosclerotic Parkinsonism | 0 | 2018 | 2018 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Congenital Zika Syndrome | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2018 | 2020 | 5.0 | high | 0 | 0 | 0 | 0 | 2 | 0 | |
| Parkinson Disease, Secondary | 0 | 2018 | 2018 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Zika Virus Infection | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |